Gemphire's gemcabene meets in Phase IIb for severe hypertriglyceridemia

By Elizabeth S. Eaton | Jun 29, 2018 | 4:48 PM GMT

Gemphire Therapeutics Inc. (NASDAQ:GEMP) reported data from the Phase IIb INDIGO-1 trial to treat severe hypertriglyceridemia showing that once-daily 600